Total investment of 16 billion! Twenty-four biopharmaceutical industry projects are located in the new area of Lingang

"Pharmaceutical Network Industry Dynamics" it is reported that the Shanghai Free Trade Zone Lingang New Area", "Life Blue Bay Biopharmaceutical Characteristics Industrial Park" was officially opened on September 10.
24 key industrial projects, such as Jia and Bio, Runjia Pharmaceuticals, signed a total investment of 16 billion yuan.
projects cover the frontiers of the biopharmaceutical industry such as molecular synthesis, immunotherapy, cell therapy, key vaccines, CDMO (contract research and development production organization), CRO (contract research organization), and 3D printing.
For example, Jia and antibody drug production base will be engaged in the research and development and commercialization of tumor and autoimmune drugs, Runjia innovative drug research and development and industrialization base focus on degenerative diseases and anti-tumor drugs, the construction of small molecule innovative drug research and development and industrialization center.
In addition, the landing of functional platforms and industry organizations such as "Lingang New Area Medical Device Technology Review Service Station", "Lingang New Area Drug Innovation Service Base" and "Lingang New Area Biopharmaceutical Industry Alliance" has further helped the biopharmaceutical industry of Life Blue Bay to develop in a characteristic and clustered way.
biopharmaceutical industry is known as the "sunrise industry", in recent years, with the support of good policies, the biopharmaceutical industry has been able to develop rapidly, expanding in scale, driving the development of biopharmaceutical industry park.
According to the 2020 China Biopharmaceutical Industry Park Development Prospects and Investment Research Report released by the China Institute of Commerce and Industry, the total industrial output value of China's Biopharmaceutical Industrial Park reached 1.82 trillion yuan in 2018, up 16.95 percent year-on-year.
forecast, by 2020, the total output value of China's biopharmaceutical industrial park will exceed 2.5 trillion yuan.
New Area also attaches great importance to the development of the biopharmaceutical industry, is currently focusing on key technology areas and links, is accelerating the construction of an open biopharmaceutical industry system with international market competitiveness, and cultivate hundreds of billions of industrial clusters.
that since this year, more than 30 biopharmaceutical enterprises have landed in new areas, investment scale of nearly 20 billion yuan.
In terms of policy support, Lingang New Area issued 10 measures in October 2019 to focus on the development of the biopharmaceutical industry, and several measures mainly support the large-scale development of enterprises in four main situations, including: incentives for the winning varieties in the procurement of national drug concentration. Encourage enterprises to open up the market, in addition to enterprise collaboration in the new film area, focus on supporting enterprises to expand international business, support the construction of research and development outsourcing and service centers, etc., to provide specialized services for biomedical research and development and production, for small and medium-sized enterprises to support their green development, to obtain the overall EIA of professional parks, do not require individual projects for EIA.
, the new zone also provides a certain subsidy incentive for the standardized collection, classification, staging and disposal of hazardous waste.
that on the basis of this policy, lingang new area will also be introduced version 2.0.
the same time, under the background of the innovation of the system of the new area in Lingang, we will promote the establishment of a fast track for the approval and review of biopharmaceutical enterprises, promote the bonded research and development of biopharmaceuticals, and further support the development of the biopharmaceutical industry.
In accordance with the development plan of the frontier industry of the new zone, by the end of the 14th Five-Year Plan, the scale of the biopharmaceutical industry in the new zone will reach 50 billion yuan, accounting for 10% of the city;